title: [Effects and side effects of hypertensive intra-arterial chemotherapy (CDDP, PEP) in advanced cancer of the uterine cervix].
abstract: We have been treating advanced cancer of the uterine cervix with intra-arterial cisplatin (CDDP) and pepleomycin (PEP) (injected into the bilateral internal iliac artery), combined with radiotherapy and hysterectomy. Concomitant angiotensin II (AT II) administered by intravenous drip infusion was double the tumoral blood flow and thereby enhanced the efficiency of the intra-arterial chemotherapeutic regimen. But CDDP runs the risk of renal and myelotoxicity, so we studied renal dysfunction after treatment by examining serum and urinary beta 2-microglobulin (beta 2-m), and RBC, Hb, WBC, lymphocyte, and PLT.
  
  
  RESULTS
  At 1 week after the treatment, evaluation of the histological effects showed, Grade IIb: 72.7% (8/11 cases). Serum beta 2-m was within normal limit and not changed. Urinary beta 2-m levels increased to abnormal levels at 1 and 2 weeks after treatment, and fell to normal levels at 3 weeks after treatment. RBC, Hb, WBC, lymphocyte, and PLT fell most at 3 weeks after treatment and then increased slowly. This suggests that hypertensive intra-arterial chemotherapy (CDDP) impaired kidney and bone marrow, mildly and reversibly, and its appropriate interval is about 4 weeks.
authors: Dept. of Obstetrics and Gynecology, Shimane Medical University.
authors: O
authors: O
authors: Iwanari
authors: Y
authors: Y
authors: Date
authors: N
authors: N
authors: Yoshino
authors: J
authors: J
authors: Miyako
authors: K
authors: K
authors: Ryukou
authors: M
authors: M
authors: Moriyama
authors: S
authors: S
authors: Nakayama
authors: M
authors: M
authors: Kitao
authors: Y
authors: Y
authors: Fujita
authors: K
authors: K
authors: Yasui
mesh_terms: D000328:Adult; D000368:Aged; D000804:Angiotensin II / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects; D001794:Blood Pressure / Q000187:drug effects; D001853:Bone Marrow / Q000187:drug effects; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003131:Combined Modality Therapy; D003864:Depression, Chemical; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007261:Infusions, Intra-Arterial; D007668:Kidney / Q000187:drug effects / Q000503:physiopathology; D008875:Middle Aged; D017663:Peplomycin; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology
chemical_list: D001761:Bleomycin; D000804:Angiotensin II; D017663:Peplomycin; D002945:Cisplatin